CAJ | 학술논문

目的观察吉非替尼单药治疗晚期非小细胞肺癌的疗效与不良反应.方法 24例Ⅲ～Ⅳ期非小细胞肺癌患者口服吉非替尼(易瑞沙)250 mg/d,1次顿服,不限疗程,直至出现严重不良反应或因经济问题或死亡而终止.观察临床症状改善情况、不良反应,通过CT扫描判断疗效.结果 24例患者中完全缓解2例,部分缓解12例,稳定6例,进展4例,有效率为58.3%,疾病控制率为83.3%,主要不良反应为腹泻.结论吉非替尼应用于放、化疗失败或不能耐受放、化疗的非小细胞肺癌患者是安全的,患者耐受性好.
목적 관찰길비체니단약치료만기비소세포폐암적료효여불량반응.방법 24례Ⅲ～Ⅳ기비소세포폐암환자구복길비체니(역서사)250 mg/d,1차돈복,불한료정,직지출현엄중불량반응혹인경제문제혹사망이종지.관찰림상증상개선정황、불량반응,통과CT소묘판단료효.결과 24례환자중완전완해2례,부분완해12례,은정6례,진전4례,유효솔위58.3%,질병공제솔위83.3%,주요불량반응위복사.결론 길비체니응용우방、화료실패혹불능내수방、화료적비소세포폐암환자시안전적,환자내수성호.
Objective To evaluate the antitumor efficacy and toxicity of gefitinib for patients with advanced non-small cell lung cancer(NSCLC)who failed to prior chemotherapy.Methods Twenty-four cases with grade Ⅲ～Ⅳ NSCLC were enrolled.Gefitinib 250 mg was administered orally once a day until intolerable toxity developing or economic problem or death.Tumer response and treatment toxicities were assessed by clinical observation and monthly CT scan.Results All 24 patients could be evaluated.Two cases got complete response.Twelve cases got paritial response.Six cases had stable response.Four cases had disease progression.So the response rate was 58.3%and the control rate was 83.3%.The main toxicities included diarrhea.Conclusions Gefitinib is effective in treatment of advanced NSCLC patients who failed to chemoradiotherapy and adverse effects are tolerable.